RAPID TUMOR LYSIS IN A PATIENT WITH B-CELL CHRONIC LYMPHOCYTIC-LEUKEMIA AND LYMPHOCYTOSIS TREATED WITH AN ANTI-CD20 MONOCLONAL-ANTIBODY (IDEC-C2B8, RITUXIMAB)

Authors
JENSEN M WINKLER U MANZKE O DIEHL V ENGERT A
Citation
M. Jensen et al., RAPID TUMOR LYSIS IN A PATIENT WITH B-CELL CHRONIC LYMPHOCYTIC-LEUKEMIA AND LYMPHOCYTOSIS TREATED WITH AN ANTI-CD20 MONOCLONAL-ANTIBODY (IDEC-C2B8, RITUXIMAB), Annals of hematology, 77(1-2), 1998, pp. 89-91
Citations number
7
Categorie Soggetti
Hematology
Journal title
Annals of hematology → ACNP
ISSN journal
09395555
Volume
77
Issue
1-2
Year of publication
1998
Pages
89 - 91
Database
ISI
SICI code
0939-5555(1998)77:1-2<89:RTLIAP>2.0.ZU;2-D
Abstract
In this report we present a patient with B-cell chronic lymphocytic le ukemia who developed an acute tumor lysis syndrome after administratio n of the human anti-CD20 antibody IDEC-C2B8 (RITUXIMAB) in standard do se of 375 mg/m(2). IDEC-C2B8 has been demonstrated to have only mild a nd tolerable side effects in patients with follicular lymphoma. In the se trials patients with lymphocytosis > 5000/mu l were excluded. Physi cians must be aware of this hitherto unreported phenomenon in patients with high CD20-positive blood counts.